- BMS partners Sprycel and Ixempra with Otsuka
- BMS and Otsuka develop and sell schizophrenia drug
- Otsuka buys PDL's IV Busulfex for $200mm
- Takeda to buy Millennium for $8.2bn in cash
- Ligand sells cancer line to Eisai for $205mm
- Eisai to acquire US biotech Morphotek for $325mm
- Eisai buys MGI Pharma
- Astellas buys Agensys for $387mm plus earn-outs
- Astellas to offer $981mm cash for CV Therapeutics; withdrawn
- Gilead steps up to buy CV Therapeutics for $20 per share
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.